State Street Corp Has $54.14 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

State Street Corp lessened its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 14.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,379,774 shares of the company's stock after selling 392,605 shares during the period. State Street Corp owned about 3.00% of Viridian Therapeutics worth $54,140,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. FMR LLC raised its stake in shares of Viridian Therapeutics by 16.8% during the 3rd quarter. FMR LLC now owns 11,183,478 shares of the company's stock worth $254,424,000 after purchasing an additional 1,610,130 shares in the last quarter. Novo Holdings A S grew its holdings in Viridian Therapeutics by 81.8% during the second quarter. Novo Holdings A S now owns 2,000,000 shares of the company's stock worth $26,020,000 after purchasing an additional 900,000 shares during the period. Maverick Capital Ltd. increased its position in Viridian Therapeutics by 22.9% during the second quarter. Maverick Capital Ltd. now owns 3,307,945 shares of the company's stock worth $43,036,000 after buying an additional 615,531 shares during the last quarter. Candriam S.C.A. increased its holdings in shares of Viridian Therapeutics by 167.8% during the 2nd quarter. Candriam S.C.A. now owns 749,804 shares of the company's stock worth $9,754,000 after acquiring an additional 469,804 shares during the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new stake in Viridian Therapeutics during the 3rd quarter valued at $9,669,000.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on VRDN shares. BTIG Research increased their price objective on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, September 26th. TD Cowen assumed coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They issued a "buy" rating on the stock. The Goldman Sachs Group boosted their price objective on Viridian Therapeutics from $25.00 to $31.00 and gave the stock a "buy" rating in a report on Thursday, September 12th. Wells Fargo & Company reiterated an "equal weight" rating and set a $27.00 target price (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday. Finally, HC Wainwright restated a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research note on Monday. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $35.70.

Viridian Therapeutics Price Performance

Shares of VRDN traded down $0.20 during trading hours on Thursday, hitting $18.73. 2,255,545 shares of the company were exchanged, compared to its average volume of 1,157,624. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -4.35 and a beta of 1.04. The firm's fifty day moving average is $21.87 and its 200 day moving average is $18.05. Viridian Therapeutics, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million. On average, equities analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, CEO Stephen F. Mahoney bought 21,400 shares of the stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $23.33 per share, with a total value of $499,262.00. Following the completion of the purchase, the chief executive officer now owns 21,400 shares in the company, valued at $499,262. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Thomas W. Beetham bought 5,000 shares of the company's stock in a transaction dated Friday, September 27th. The stock was bought at an average cost of $23.41 per share, with a total value of $117,050.00. Following the acquisition, the chief operating officer now directly owns 6,000 shares of the company's stock, valued at approximately $140,460. The trade was a 500.00 % increase in their position. The disclosure for this purchase can be found here. 0.65% of the stock is currently owned by insiders.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.